Nicotinamide mononucleotide potentiates the anti-tumor efficacy of CAR-NK cell therapy targeting MSLN in ovarian cancer.

NMN supplementation significantly enhances the efficacy of CAR-NK cell immunotherapy against ovarian cancer by improving NK cell activation, cytokine production, and cytotoxic capacity while protecting cells from tumor microenvironment-induced oxidative stress. The mechanism involves modulation of phosphorylation cascades and mitochondrial redox homeostasis. In xenograft models, NMN-preconditioned CAR-NK cells achieved superior tumor control and enhanced intratumoral infiltration, positioning NMN as a clinically translatable metabolic adjuvant for improving cancer immunotherapy outcomes.

For your business

NMN preconditioning enhanced CAR-NK cytotoxicity in ovarian cancer xenografts; supports NMN’s role in immune cell metabolic resilience.

Read more on Cancer Gene Ther →

Shopping Cart
Scroll to Top